Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes

Leukemia volume 28, pages 2241–2244 (2014)Cite this article

Subjects

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell (HSC) malignancies that are characterized by ineffective bone marrow hematopoiesis, peripheral blood cytopenias and a substantial risk of progression to acute myeloid leukemia.1, 2, 3 There is evidence that alterations of the direct interaction between HSCs and stroma contribute to abnormal HSC growth and maturation.4

Mesenchymal stem cells (MSCs) have been defined as non-hematopoietic cells that primarily reside in bone marrow (BM) and are capable of producing different cell lineages. They are important components of the hematopoietic microenvironment and are important in supporting and regulating the proliferation and differentiation of hematopoietic stem cells, as well as in immunoregulatory functions.5

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Mufti GJ . Pathobiology, classification, and diagnosis of myelodysplastic syndromes. Best Pract Res Clin Haematol 2004; 17: 543–557.

    Article  Google Scholar 

  2. Nimer SD . Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008; 87: 777–795.

    Article  Google Scholar 

  3. Kerbauy DB, Deeg HJ . Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndromes. Exp Hematol 2007; 35: 1739–1746.

    Article  CAS  Google Scholar 

  4. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ . Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002; 16: 785–790.

    Article  CAS  Google Scholar 

  5. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I . The role of mesenchymal stem cells in hematopoiesis. Blood Rev 2006; 8: 315–317.

    Google Scholar 

  6. Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 2006; 20: 329–335.

    Article  CAS  Google Scholar 

  7. Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27: 1841–1851.

    Article  CAS  Google Scholar 

  8. Guerzoni C, Amatori S, Giorgi L, Manara MC, Landuzzi L et al. An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer 2014; 14: 137.

    Article  Google Scholar 

  9. Wagner W, Bork S, Lepperdinger G, Joussen S, Ma N, Strunk D et al. How to track cellular aging of mesenchymal stromal cells? Aging (Albany NY) 2010; 2: 224–230.

    Article  CAS  Google Scholar 

  10. Poloni A, Maurizi G, Babini L, Serrani F, Berardinelli E, Mancini S et al. Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant 2011; 20: 643–654.

    Article  Google Scholar 

  11. Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S et al. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 2008; 27: 358–365.

    Article  CAS  Google Scholar 

  12. Poloni A, Goteri G, Zizzi A, Serrani F, Trappolini S, Costantini B et al. Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. Eur J Haematol 2013; 91: 219–227.

    Article  CAS  Google Scholar 

  13. Romermann D, Hasemeier B, Metzing K, Schlegelberger B, Länger F, Kreipe H et al. Methylation status of LINE-1 sequences in patients with MDS or secondary AML. Verh Dtsch Ges Pathol 2007; 91: 338–342.

    CAS  PubMed  Google Scholar 

  14. Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E et al. Impaired proliferative potential of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev 2014; 23: 1568–1581.

    Article  CAS  Google Scholar 

  15. Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 2014; 14: 824–837.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Associazione Italiana contro le leucemie, linfomi e mieloma, sezione di Ancona-ONLUS. The English was edited by Timothy Wills.

Author information

Author notes

  1. A Poloni and G Maurizi: These authors contributed equally to this work.

Authors and Affiliations

  1. Dipartimento di Scienze Cliniche e Molecolari, Clinica di Ematologia, Università Politecnica delle Marche, Ancona, Italy

    A Poloni, G Maurizi, D Mattiucci, B Costantini, M Mariani, S Mancini, A Olivieri & P Leoni

  2. Dipartimento di Scienze Biomolecolari, Laboratorio di Patologia Molecolare ‘PaoLa’, Università di Urbino ‘Carlo Bo’, Fano, Italy

    S Amatori, B Fogliardi & M Fanelli

Authors
  1. A Poloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Maurizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Mattiucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Amatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Fogliardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Costantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Mariani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Mancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Fanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Leoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to A Poloni or M Fanelli.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poloni, A., Maurizi, G., Mattiucci, D. et al. Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes. Leukemia 28, 2241–2244 (2014). https://doi.org/10.1038/leu.2014.197

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.197

This article is cited by

Search

Advanced search

Quick links